Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)

Inclusion Criteria: * Durie-Salmon stage IIA-IIIB multiple myeloma * Age \> 18 and ≤ 65 years * Previously untreated myeloma * Presence of a sibling (potential donor) * Bilirubins \< twice normal;ALAT and ASAT \< four times normal * Left ventricular ejection fraction \> 40% * Creatinine clearances \> 40 mL/min * Pulmonary dysfunction with diffusing capacity for carbon monoxide (DLCO) \> 40% and/or need for continuous oxygen supplementation * Karnofsky performance status \> 60% * Patients must give written informed consent Exclusion Criteria: * Age \> 65 years * Previously treated myeloma * Absence of a sibling (genetic randomisation cannot be applied) * Karnofsky performance status score \< 60% * HIV-infection * Pregnancy * Refusal to use contraceptive techniques during and for 12 months following treatment * Patients unable to give written informed consent * PS. Informed consent is obtained from each patient according to the Institutional Review Boards of the participating centers. The study is conducted according to the Declaration of Helsinki.